The Journal of Urology
Volume 181, Issue 4 , Pages 1628-1634, April 2009

Pathological Outcomes of Candidates for Active Surveillance of Prostate Cancer

  • Simon L. Conti
  • ,
  • Marc Dall'Era
  • ,
  • Vincent Fradet

      Affiliations

    • Recipient of the McLaughlin Dean's grant, Laval University.
  • ,
  • Janet E. Cowan

      Affiliations

    • Financial interest and/or other relationship with TAP Pharmaceutical Products, Inc.
  • ,
  • Jeffery Simko

      Affiliations

    • Financial interest and/or other relationship with BioImagene, Abbott Molecular, Genomic Health, Amgen and Genentech.
  • ,
  • Peter R. Carroll

      Affiliations

    • Corresponding Author InformationCorrespondence: Department of Urology, 1600 Divisadero St., Room A628, San Francisco, California 94143-1695 (telephone: 415-353-7098; FAX: 415-353-7093)
    • Financial interest and/or other relationship with TAP Pharmaceuticals, National Cancer Institute and AstraZeneca.

Department of Urology, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California

Received 18 August 2008 published online 23 February 2009.

Purpose

Active surveillance of prostate cancer has emerged as a viable treatment option for men with features of low risk disease. Five prospective studies have enrolled patients for active surveillance with varying inclusion criteria. We evaluated the pathological outcomes of men meeting published criteria for active surveillance who elected immediate radical prostatectomy to assess the risk of under grading and under staging in candidates for active surveillance.

Materials and Methods

Data were extracted from our institutional urological oncology database for all men who underwent radical prostatectomy between 1996 and 2007. The primary outcome was pathological up staging, defined as the occurrence of extracapsular extension or seminal vesicle involvement. Pathological upgrading was identified as a secondary outcome. We determined the proportion of men who would have qualified for each published active surveillance study and the respective rates of upgrading and up staging in each group.

Results

We identified 1,097 men who underwent radical prostatectomy with a mean age of 59 years. Overall 28% of the men experienced a Gleason upgrade, 21% had extracapsular extension and 11% had seminal vesicle involvement. In men qualifying based on published active surveillance inclusion criteria, rates of upgrading varied between 23% and 35%, the incidence of extracapsular extension ranged from 7% to 19% and seminal vesicle involvement ranged from 2% to 9%.

Conclusions

Varying entry criteria for active surveillance show different rates of adverse pathological features at radical prostatectomy. Predictably fewer men met the more stringent criteria but these men had a lower incidence of seminal vesicle involvement and extracapsular extension. Such data can be used to advise men of the risks of active surveillance.

Key Words: prostatic neoplasms, patient selection, neoplasm staging, pathology

Abbreviations and Acronyms: DRE, digital rectal examination, ECE, extracapsular extension, PSA, prostate specific antigen, PSAD, prostate specific antigen density, RP, radical prostatectomy, SVI, seminal vesicle involvement, TRUS, transrectal ultrasound, UCSF, University of California, San Francisco, UODB, urological oncology database

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Study received institutional review board approval.

 Supported by National Institutes of Health Prostate Cancer SPORE Grant 1P50CA089520-01.

 See Editorial on page 1534.

PII: S0022-5347(08)03270-9

doi:10.1016/j.juro.2008.11.107

Refers to article:

  • Prostate Specific Antigen Screening and Active Surveillance in the Elderly , 23 February 2009

    Badrinath R. Konety
    The Journal of Urology April 2009 (Vol. 181, Issue 4, Pages 1534-1535)

The Journal of Urology
Volume 181, Issue 4 , Pages 1628-1634, April 2009